skip to Main Content

HaemoSys – good development secures finance

  • 2005

bm|t beteili­gungs­man­age­ment thürin­gen gmbh and another investor are financ­ing the growth of HaemoSys GmbH, Jena. In the frame­work of an increase in cap­i­tal, the two investors are pro­vid­ing the com­pany with suf­fi­cient resources to reach the next mile­stone in the devel­op­ment of inno­v­a­tive prod­ucts. The injec­tion of funds is aimed par­tic­u­larly at tests for newly devel­oped blood filters.

Non-Intrusive Therapy for Serious Chronic Diseases

HaemoSys GmbH is devel­op­ing new types of med­i­c­i­nal prod­ucts for ther­a­peu­tic and diag­nos­tic appli­ca­tions using ver­sa­tile basic techniques.

The focus of the Jena com­pany is the devel­op­ment of spe­cific blood purifi­ca­tion pro­ce­dures pro­vid­ing ther­apy for severe dis­or­ders which are cur­rently not cur­able or only unsat­is­fac­to­rily so. A par­tic­u­lar advan­tage of the ther­apy is that it has no side effects.

Ini­tial inno­v­a­tive diag­nos­tic tests by HaemoSys for the early recog­ni­tion of blood clot­ting dis­or­ders, which often cause strokes and heart attacks are already avail­able. After pos­i­tive pre-clin­i­cal tri­als, HaemoSys is now prepar­ing the clin­i­cal test phase for the blood filters.

HaemoSys was founded in 1999 and cur­rently employs 16 staff.


HaemoSys GmbH
Dr. Elke Bucha

Winz­er­laer Str. 2
D‑07745 Jena
+49 (0) 3641 508–300
+49 (0) 3641 508–301

Back To Top
×Close search